CommercialCoverageMedium impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Hematology, Oncology, Endocrinology +2 more·Medical Policy
Effective date
Nov 1, 2025
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross updated coverage criteria for Abatacept (Orencia) to include new coverage for acute graft vs. host disease prophylaxis in stem cell transplant patients aged 2+ years. Additionally, thyroid disease testing coverage was restricted to exclude routine screening in asymptomatic, non-pregnant individuals during general exams without abnormal findings.
Action Required
By November 1, 2025: Update prior authorization processes for Abatacept (Orencia) to include new GVHD prophylaxis indication for stem cell transplant patients. Verify patient meets age requirements (2+ years), transplant criteria (HLA matched/1-allele mismatched donors), and combination therapy requirements. For thyroid testing, stop billing routine thyroid screening for asymptomatic non-pregnant patients during general exams - claims will be denied for non-coverage.